WAVE Life Sciences Liabilities 2024

WAVE Life Sciences Aktienanalyse

What does WAVE Life Sciences do?

WAVE Life Sciences Ltd is a biotechnology company dedicated to the development of nucleic acid preparations for the treatment of genetically inherited diseases. The company was founded in 2012 and is headquartered in Singapore. WAVE Life Sciences' business model is focused on developing specific nucleic acid sequences that can selectively silence or correct defective genes associated with various diseases. The company offers these sequences as therapeutics that enable personalized treatment for patients. The company utilizes a proprietary platform technology called "AVIENNA" to selectively silence or correct defective genes. "AVIENNA" aims to optimize the physical properties of nucleic acids to improve their effectiveness and duration of action. WAVE Life Sciences has three business areas: neurology, cardiovascular diseases, and metabolic diseases. In the neurology area, the company focuses on the development of therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington's disease. In the cardiovascular diseases area, the company is working on therapeutics for cardiovascular diseases such as heart attack, stroke, and atherosclerosis. In the metabolic diseases area, WAVE Life Sciences is focused on the development of therapeutics for rare metabolic diseases such as Crohn's disease and Pompe disease. The most well-known product in WAVE Life Sciences' pipeline is "WVE-120101", a therapeutic for the treatment of ALS. The drug has been developed to target mutations in the SOD1 gene that can lead to ALS. WVE-120101 is currently in clinical trials and has the potential to become the first approved medication for patients with ALS. WAVE Life Sciences also collaborates closely with other companies to exchange technologies and know-how. In 2018, the company entered into a strategic partnership with Takeda Pharmaceutical to jointly develop therapeutics for the treatment of gastrointestinal diseases. The partnership aims to leverage the strengths of both companies and accelerate the development of innovative therapeutics. Overall, WAVE Life Sciences has a promising portfolio of therapeutics that have the potential to improve the lives of patients with genetically inherited diseases. The company follows a systematic and scientifically-based strategy in drug development to ensure the effectiveness and safety of its products. With its innovative business model and dedicated research and development, WAVE Life Sciences is well positioned to achieve a leading position in the biotechnology industry in the future. WAVE Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing WAVE Life Sciences's Liabilities

WAVE Life Sciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating WAVE Life Sciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing WAVE Life Sciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

WAVE Life Sciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in WAVE Life Sciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about WAVE Life Sciences stock

What is the level of liabilities of WAVE Life Sciences this year?

WAVE Life Sciences has a debt balance of 227.45 M USD this year.

What were the liabilities of WAVE Life Sciences compared to the previous year?

The liabilities of WAVE Life Sciences have increased by 23.88% increased compared to the previous year.

What are the consequences of high debt for investors of WAVE Life Sciences?

High liabilities can pose a risk for investors of WAVE Life Sciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in WAVE Life Sciences?

Low liabilities mean that WAVE Life Sciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of WAVE Life Sciences affect the company?

An increase in liabilities of WAVE Life Sciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of WAVE Life Sciences affect the company?

A decrease in the liabilities of WAVE Life Sciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of WAVE Life Sciences?

Some factors that can influence the liabilities of WAVE Life Sciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of WAVE Life Sciences so important for investors?

The liabilities of WAVE Life Sciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can WAVE Life Sciences take to modify the liabilities?

To change its liabilities, WAVE Life Sciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does WAVE Life Sciences pay?

Over the past 12 months, WAVE Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WAVE Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of WAVE Life Sciences?

The current dividend yield of WAVE Life Sciences is .

When does WAVE Life Sciences pay dividends?

WAVE Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of WAVE Life Sciences?

WAVE Life Sciences paid dividends every year for the past 0 years.

What is the dividend of WAVE Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is WAVE Life Sciences located?

WAVE Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von WAVE Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of WAVE Life Sciences from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did WAVE Life Sciences pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of WAVE Life Sciences in the year 2023?

In the year 2023, WAVE Life Sciences distributed 0 USD as dividends.

In which currency does WAVE Life Sciences pay out the dividend?

The dividends of WAVE Life Sciences are distributed in USD.